Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Anna Christofides
 -- 1194 2022-06-15 15:01:47 |
2 update layout and references
Rita Xu
 Meta information modification 1194 2022-06-16 03:21:31 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Christofides, A.; Owen, C.; , . COVID-19 Patients with Hematologic Malignancies. Encyclopedia. Available online: https://encyclopedia.pub/entry/24067 (accessed on 07 October 2024).
Christofides A, Owen C,  . COVID-19 Patients with Hematologic Malignancies. Encyclopedia. Available at: https://encyclopedia.pub/entry/24067. Accessed October 07, 2024.
Christofides, Anna, Carolyn Owen,  . "COVID-19 Patients with Hematologic Malignancies" Encyclopedia, https://encyclopedia.pub/entry/24067 (accessed October 07, 2024).
Christofides, A., Owen, C., & , . (2022, June 15). COVID-19 Patients with Hematologic Malignancies. In Encyclopedia. https://encyclopedia.pub/entry/24067
Christofides, Anna, et al. "COVID-19 Patients with Hematologic Malignancies." Encyclopedia. Web. 15 June, 2022.
COVID-19 Patients with Hematologic Malignancies
Edit
This entry is adapted from the peer-reviewed paper 10.3390/curroncol29060315

Patients with hematological malignancies have an increased risk of serious outcomes following COVID-19 infection, suggesting broader protection is needed beyond vaccination. Monoclonal antibodies such as sotrovimab, casirivimab–imdevimab, and bamlanivimab have provided valuable options for the treatment of COVID-19 disease. More recently, monoclonal antibodies have been examined for the prevention of COVID-19 infection.

COVID-19 coronavirus hematology malignancy

1. Introduction

Since the COVID-19 pandemic was first reported in China in December 2019, cases have exploded globally, with a total of 3.3 million cases and 36,630 deaths reported in Canada as of 2 March 2022 [1]. Although people of all ages are at risk of infection, the probability of more serious disease is greater in people with chronic medical conditions, who are 60 years or older, or who are living in nursing homes or long-term care facilities [2]. People who are immunocompromised are one such group with an increased risk of serious outcomes following COVID-19 infection [3]. Immunocompromising conditions are defined as those that suppress humoral or cellular immunity as a result of health conditions or medications [4]. Based on data from Statistics Canada, about 14% of Canadians fit into this higher-risk immunocompromised category [5]. Examples of patients with immunocompromising conditions include [6]:
  • Active treatment for solid tumor and hematologic malignancies;
  • Receipt of a solid-organ transplant and taking immunosuppressive therapy;
  • Chimeric antigen receptor (CAR) T-cell therapy or hematopoietic stem cell transplant (HSCT);
  • Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott–Aldrich syndrome);
  • Advanced or untreated human immunodeficiency virus (HIV) infection.
In addition to having an increased risk of severe outcomes from COVID infection, studies have shown that people who are immunocompromised do not have the same level of protection from COVID-19 mRNA vaccines [7][8][9]. Real-world vaccine studies have shown high effectiveness in the general population, ranging from 65% to 90% against infection or mild disease and 90% to 100% against severe infection after two doses of BNT162b2 (Pfizer), AZD1222 (AstraZeneca), or mRNA-1273 (Moderna) [10][11][12][13]. However, vaccine effectiveness rates in immunocompromised populations after two doses of an mRNA vaccine are lower, at around 60% against clinical disease [9] and 77% against hospitalization [4]. Vaccine effectiveness varies widely even within the immunocompromised population, ranging from 59% (e.g., solid organ transplant) to 81% (e.g., rheumatoid arthritis) against hospitalization [4]. Moreover, there is a lack of clinical access to effective antibody testing for vaccine response in Canada and these tests have not been adequately evaluated for their ability to determine immunity or protection from COVID-19 [14]. It is therefore difficult to predict how people will respond to vaccination and their level of protection from severe COVID-19 outcomes. In addition, with the advent of new variants of concern (VOCs), such as Omicron (subvariants BA.1, BA.1.1. and BA.2), vaccine effectiveness against hospitalization has been reduced, requiring three doses in order to achieve comparable protection to two doses with the Delta (B.1.617.2) variant [15]. As of 5 April 2022, the National Advisory Committee on Immunization has also recommended a fourth dose of a COVID-19 vaccine in Canada, prioritizing adults 80 years of age and over and residents of long-term care homes and congregate living centers [16]. A discretionary recommendation is also given for adults 70–79 years of age. It is expected that the introduction of a third and fourth dose of a COVID-19 vaccine will increase the response and provide additional protection in a proportion of patients [17][18].

2. Risk of COVID-19 in Patients with Hematologic Malignancies

Patients with hematological malignancies, such as leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas, and multiple myeloma, have an increased risk of infections as a result of disease-related immune dysregulation [19]. In addition, many commonly used treatments may have an immunosuppressive effect, adding to the risk of infection [19]. For example, treatment with B-cell-targeting therapies, resulting in B-cell depletion and/or disruption of the B-cell receptor signaling pathway, may adversely affect the production of antibodies in response to COVID-19 vaccination [20]. B-cell recovery may also be slow in these patients; for example, in lymphoma patients, recovery was shown to remain below normal controls one year after administration of rituximab [21]. In addition, patients undergoing HSCT are at particularly high risk of immunosuppression due to impairment in innate and adaptive immunity [22]. In the case of allogeneic HSCT, patients generally need ongoing immune suppressive therapy to treat and prevent graft-versus-host disease [22]. Although data are limited, preliminary studies suggest patients with hematological malignancies who are receiving CD19-directed CAR T-cell therapy also have a reduced response to COVID-19 vaccines [23].
Seroconversion rates following COVID-19 vaccination have shown to be reduced in patients with hematologic malignancies. An Israeli study in 427 people showed that a lower proportion of those with hematologic malignancies were seropositive after COVID-19 vaccination than in an immunocompetent comparator group (75% vs. 99%; p < 0.001) [24]. Moreover, patients treated for hematologic malignancies (n = 164) had significantly less seropositive responses (e.g., immunochemotherapy (29%); anti-CD20 antibodies (0%); or BCL2 (25%), BTK (40%), or JAK2 (42%) inhibitors; p < 0.001) [24]. In addition, the prospective CAPTURE (COVID-19 antiviral response in a pan-tumor immune monitoring) study showed seroconversion rates following COVID-19 vaccination were lower in 21 patients with haematological malignancies (59%) than in those with solid tumours (85%) [25]. Overall, 81% had received chemotherapy, 48% had received targeted therapy, and 29% had received anti-CD20 therapies in the 12 weeks prior to vaccination. In addition, a study of 121 patients with non-Hodgkin’s lymphoma, including chronic lymphocytic leukemia (CLL), showed an 85-fold reduction in mean anti-SARS-CoV-2 spike immunoglobulin G–binding titers in these patients compared with healthy controls, with seroconversion occurring in only 67% of patients [26]. Overall, 47% of patients had received anti-CD20-directed therapy within one year prior to COVID-19 vaccination. Finally, a systematic review of five studies examining the response to COVID-19 vaccination in a total of 70 patients receiving CAR T-cell therapy, showed a low cumulative humoral response rate of 31% [23].
A number of studies have shown patients with hematologic malignancies are at increased risk of severe outcomes following infection with COVID-19. A study by Mittelman et al. showed that among 32,516 vaccinated patients with hematologic malignancies, the relative risk for COVID-19 infection (1.60; 95% CI, 1.12–2.37) and hospitalization (3.13; 95% CI, 1.68–7.08) was significantly greater, compared with matched controls [27]. Overall, 5107 (15.9%) patients were receiving active treatment for a hematological malignancy. In addition, a study examined data from the VISION Network, which included 20,101 immunocompromised patients aged ≥ 18 years with COVID-19-like illness discharged from 187 hospitals across nine states in the United States [4]. Results showed that in patients with hematological malignancies, vaccine effectiveness against hospitalization was around 74% (95% CI: 62%, 83%), versus 90% (95% CI: 89%, 91%) in immunocompetent patients who had received two doses of an mRNA vaccine two weeks prior to hospitalization. In addition, a study in 2767 patients with non-Hodgkin lymphoma showed those receiving active treatment given within 30 days of COVID-19 diagnosis (n = 195) had more severe outcomes than those not receiving treatment (OR 1.4; 95% CI 1.0, 2.0) [28]. Two large multicenter retrospective studies have also reported high rates of severe COVID-19 disease and mortality in both untreated as well as treated patients with CLL [29][30]. In one of the studies [26], survival rates were not associated with active treatment, whereas in the second study [27], significantly more patients (91/151, 60.3%) in the severe COVID-19 group were off treatment within the last year or had never received treatment for CLL compared with less severe cases (15/39, 38.5%) (p < 0.05). Finally, The Center for International Blood and Marrow Transplant Research (CIBMTR) found that severe COVID-19 disease requiring mechanical ventilation occurred in 45/318 (14%) of HSCT recipients and thirty-day survival was around 67% [22]. Given the increased risk of severe COVID-19 outcomes in patients with hematologic malignancies, broader protection is needed beyond vaccination.

References

  1. COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Available online: https://github.com/CSSEGISandData/COVID-19 (accessed on 2 March 2022).
  2. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available online: https://www.covid19treatmentguidelines.nih.gov/ (accessed on 3 March 2022).
  3. Williamson, E.J.; Walker, A.J.; Bhaskaran, K.; Bacon, S.; Bates, C.; Morton, C.E.; Curtis, H.J.; Mehrkar, A.; Evans, D.; Inglesby, P.; et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020, 584, 430–436.
  4. Embi, P.J.; Levy, M.E.; Naleway, A.L.; Patel, P.; Gaglani, M.; Natarajan, K.; Dascomb, K.; Ong, T.C.; Klein, N.P.; Liao, I.C.; et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults—Nine States. MMWR Morb. Mortal. Wkly. Rep. 2021, 70, 1553–1559.
  5. Statistics Canada. Health Reports: Health-Related Concerns and Precautions during the COVID-19 Pandemic: A Comparison of Canadians with and without Underlying Health Conditions; Statistics Canada: Ottawa, ON, Canada, 2020.
  6. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Evusheld™ (Tixagevimab Co-Packaged with Cilgavimab). Available online: https://www.fda.gov/media/154701/download (accessed on 3 March 2022).
  7. Deepak, P.; Kim, W.; Paley, M.A.; Yang, M.; Carvidi, A.B.; Demissie, E.G.; El-Qunni, A.A.; Haile, A.; Huang, K.; Kinnett, B.; et al. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: A Prospective Cohort Study. Ann. Intern. Med. 2021, 174, 1572–1585.
  8. Tenforde, M.W.; Patel, M.M.; Ginde, A.A.; Douin, D.J.; Talbot, H.K.; Casey, J.D.; Mohr, N.M.; Zepeski, A.; Gaglani, M.; McNeal, T.; et al. Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing COVID-19 Hospitalizations in the United States. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2021, 74, 1515–1524.
  9. Whitaker, H.J.; Tsang, R.S.; Byford, R.; Andrews, N.J.; Sherlock, J.; Pillai, P.S.; Williams, J.; Button, E.; Campbell, H.; Sinnathamby, M.; et al. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups. J. Infect. 2022, 84, 675–683.
  10. Lopez Bernal, J.; Andrews, N.; Gower, C.; Robertson, C.; Stowe, J.; Tessier, E.; Simmons, R.; Cottrell, S.; Roberts, R.; O’Doherty, M.; et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study. BMJ 2021, 373, n1088.
  11. Hall, V.J.; Foulkes, S.; Saei, A.; Andrews, N.; Oguti, B.; Charlett, A.; Wellington, E.; Stowe, J.; Gillson, N.; Atti, A.; et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): A prospective, multicentre, cohort study. Lancet 2021, 397, 1725–1735.
  12. Dagan, N.; Barda, N.; Kepten, E.; Miron, O.; Perchik, S.; Katz, M.A.; Hernán, M.A.; Lipsitch, M.; Reis, B.; Balicer, R.D. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N. Engl. J. Med. 2021, 384, 1412–1423.
  13. Bruxvoort, K.J.; Sy, L.S.; Qian, L.; Ackerson, B.K.; Luo, Y.; Lee, G.S.; Tian, Y.; Florea, A.; Takhar, H.S.; Tubert, J.E.; et al. Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study. Lancet Reg. Health Am. 2022, 6, 100134.
  14. Antibody Testing Is Not Currently Recommended to Assess Immunity after COVID-19 Vaccination: FDA Safety Communication. 2021. Available online: https://www.fda.gov/medical-devices/safety-communications/antibody-testing-not-currently-recommended-assess-immunity-after-covid-19-vaccination-fda-safety (accessed on 28 March 2022).
  15. Lauring, A.S.; Tenforde, M.W.; Chappell, J.D.; Gaglani, M.; Ginde, A.A.; McNeal, T.; Ghamande, S.; Douin, D.J.; Talbot, H.K.; Casey, J.D.; et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: Prospective observational study. BMJ 2022, 376, e069761.
  16. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). 2022. Available online: https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/naci-guidance-second-booster-dose-covid-19-vaccines.pdf (accessed on 14 April 2022).
  17. Herishanu, Y.; Rahav, G.; Levi, S.; Braester, A.; Itchaki, G.; Bairey, O.; Dally, N.; Shvidel, L.; Ziv-Baran, T.; Polliack, A.; et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood 2022, 139, 678–685.
  18. Bar-On, Y.M.; Goldberg, Y.; Mandel, M.; Bodenheimer, O.; Amir, O.; Freedman, L.; Alroy-Preis, S.; Ash, N.; Huppert, A.; Milo, R. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. N. Engl. J. Med. 2022, 386, 1712–1720.
  19. Passamonti, F.; Cattaneo, C.; Arcaini, L.; Bruna, R.; Cavo, M.; Merli, F.; Angelucci, E.; Krampera, M.; Cairoli, R.; Della Porta, M.G.; et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: A retrospective, multicentre, cohort study. Lancet Haematol. 2020, 7, e737–e745.
  20. Ghione, P.; Gu, J.J.; Attwood, K.; Torka, P.; Goel, S.; Sundaram, S.; Mavis, C.; Johnson, M.; Thomas, R.; McWhite, K.; et al. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies. Blood 2021, 138, 811–814.
  21. Anolik, J.H.; Friedberg, J.W.; Zheng, B.; Barnard, J.; Owen, T.; Cushing, E.; Kelly, J.; Milner, E.C.; Fisher, R.I.; Sanz, I. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin. Immunol. 2007, 122, 139–145.
  22. Sharma, A.; Bhatt, N.S.; St Martin, A.; Abid, M.B.; Bloomquist, J.; Chemaly, R.F.; Dandoy, C.; Gauthier, J.; Gowda, L.; Perales, M.A.; et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: An observational cohort study. Lancet Haematol. 2021, 8, e185–e193.
  23. Abid, M.A.; Abid, M.B. SARS-CoV-2 vaccine response in CAR T-cell therapy recipients: A systematic review and preliminary observations. Hematol. Oncol. 2022, 40, 287–291.
  24. Herzog Tzarfati, K.; Gutwein, O.; Apel, A.; Rahimi-Levene, N.; Sadovnik, M.; Harel, L.; Benveniste-Levkovitz, P.; Bar Chaim, A.; Koren-Michowitz, M. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. Am. J. Hematol. 2021, 96, 1195–1203.
  25. Fendler, A.; Au, L.; Shepherd, S.T.C.; Byrne, F.; Cerrone, M.; Boos, L.A.; Rzeniewicz, K.; Gordon, W.; Shum, B.; Gerard, C.L.; et al. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: The CAPTURE study. Nat. Cancer 2021, 2, 1321–1337.
  26. Chang, A.; Akhtar, A.; Linderman, S.L.; Lai, L.; Orellana-Noia, V.M.; Valanparambil, R.; Ahmed, H.; Zarnitsyna, V.I.; McCook-Veal, A.A.; Switchenko, J.M.; et al. Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. J. Clin. Oncol. 2022, JCO2200088.
  27. Mittelman, M.; Magen, O.; Barda, N.; Dagan, N.; Oster, H.S.; Leader, A.; Balicer, R. Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting. Blood 2022, 139, 1439–1451.
  28. Yue, X.; Hallett, D.; Liu, Y.; Iyengar, R.; Basa, E.; Yang, H. Characteristics and Outcomes of COVID-19 Patients with Mature B-Cell Non-Hodgkin Lymphomas (mB-Cell NHL): A US Nationwide Electronic Health Record (EHR) Database Study. Am. Soc. Hematol. Meet. 2021, 138, 2418.
  29. Mato, A.R.; Roeker, L.E.; Lamanna, N.; Allan, J.N.; Leslie, L.; Pagel, J.M.; Patel, K.; Osterborg, A.; Wojenski, D.; Kamdar, M.; et al. Outcomes of COVID-19 in patients with CLL: A multicenter international experience. Blood 2020, 136, 1134–1143.
  30. Scarfò, L.; Chatzikonstantinou, T.; Rigolin, G.M.; Quaresmini, G.; Motta, M.; Vitale, C.; Garcia-Marco, J.A.; Hernández-Rivas, J.; Mirás, F.; Baile, M.; et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: A joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia 2020, 34, 2354–2363.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Oncology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Anna Christofides
,
Carolyn Owen
,
View Times: 263
Revisions: 2 times (View History)
Update Date: 16 Jun 2022
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback